{"name":"Connect Biopharm LLC","slug":"connect-biopharm-llc","ticker":"","exchange":"","domain":"connectbiopharmllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPTWpXc3VzY3BHVkgtSzBYbE4zc2Rkenc4ZGNYUUZCenVDaEVXdGtYT1pEVWlsWjNmQnplMjNPQjdsaVRhOFdQUDN1eUdUTFQwZUxfOUIwa2NZdFJhZk5lQXZ0ZWpmQzkwY3lLb1dtSnQ2dGlWamJ2NTFhckFreFZNbmtyLXJ2T3lPeG0yMENQOFgxdEhobklMU2VHOVBLYUNyX01iVjRyOVdRZTM2WDB6MncwUk96aUM2TElVRmVDSWFpaTBIU1pXQWJWNUJCcXlsTHBwYmJXdUNDYVFPT09TeVBEaW1HZ0xqMG1MdlgxcF9YTVBRVEIyR3d3anRnTUptcGhsQktRazlzNk9HTmtTV2ZNMGNxOEw3QTR6QThFbDZUazBOekJlRlRmV3Z0b2h4ckdnYnlqMDFvU25rVVdRV1ZTaTFJVl9aZFdzOUEyM3M?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene","headline":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBGTDRzTjNxRzJRY3F0ZW1hXzNQRGJ5UW9ibzh1SENTczlrZlJ0dmtBajhNYzJJSWxGSGFHYnhvbkh5cG9PeFpNMVFzN3lLMWtEZ1dRajJVb1VLbzR1Q1JyR0NYWVdmbVc5S1lEMUs2RlVOMklBOS1F?oc=5","date":"2026-04-05","type":"pipeline","source":"BUCKSCO.Today","summary":"Two Life Sciences Companies with Doylestown Connections Raise $119M - BUCKSCO.Today","headline":"Two Life Sciences Companies with Doylestown Connections Raise $119M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMnNiT2FfLUdzSjByTDk3UkszTmVvNVdDRFAwanBWN3RRQ1A1elJ0XzNVazAtQmFhbm0zM3I5RmtTOXVuenpHTExiUm1iVkV1bVY3cUJYVjZhbFo2TmRvZ0pGRzBaLUFWMmIwVGlMc19kbEhqc2ViUWNKbkxpd2xudEJ5bDlrNGNObmQtalJMTzFHc1NzaTF3V2d1eG5sRmQtT29LRERFMFd0NWZTN0dod3pwQmJGVGRq?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy - Stock Titan","headline":"Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5MaVBucWpvODhWZUNXZmVuMklFZkRlck81aFRIUk05U3hVdmJSeVBXb0pVLVNtUjN2aEUwSXVXWTBnamxJRHBFS0FuTVZNdDgyRkx5eUUwODhGRE00YWdoT0hyRS13QQ?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"CNTB SEC Filings - Connect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"CNTB SEC Filings - Connect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQb082MFprbTJ4SmVWOTFMU3RRanhUckhQU1RXZ2xDZnZRUUo4NXBrV1d1N0lwaHp2cllrMXNNcXRVY1hjMU5KRDhLb0xkVjllYVcxZFl2eFByM01jS3cxZ2lPWjVFRVYwREVIYWZLLXE5anRUaUNUV1dVTlQxZlh2WGFHYjlrWjRfZmlGV2lzajJqTjRQQjlaUy1BWmNDeWoyX0dKY0xDclB5akYxWmllVHgxblJxa0JSa2Z1RWhPWQ?oc=5","date":"2026-03-06","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC - Fierce Pharma","headline":"Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNcjdKeWpFY3dhVG5DZTMyT2FPOFFyY1VBaVliR2cxNHl0bEwzZHAxczdXUTl5U082a3Zmd1VmQUZnQk9rOU9qTHdfSmc1d3U1RXdDdjdKMGdGalFzRG9wRmZ0dG5mOVVQN3VEN25sSnVWNUY1d3k1dTc3bE83VG40QVNqX0o4bVFVWjF6WXVfYjV0SEtLX1E?oc=5","date":"2026-03-04","type":"pipeline","source":"Yahoo Finance","summary":"SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Yahoo Finance","headline":"SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQa1VsNlI0Z2RfQmQ4UVY1WWhpVHlKZnVuSGVwWHNzLXNqalJyeG1kLWxJU2ZzN1dXQl9pOUxVeWM2RXFsRlhPWFJJMjZGRm16aGtjNzg1ZDNBb1FDMkZuNTVPMHUyMVVsekljeHdpNkRhd2d1UGhvUHVmc2ZzUUh3YXBRNzJvaE1mTGx0Mk4tNV9WQ3g1S1pYcU82Z1ZaUHgzem5rLTVMXzlTWXc3bDVYNGdscGxqVlhiNTFKSTlURWwtSS1wYm5lWVQ3ckhzZE1Z?oc=5","date":"2026-01-13","type":"pipeline","source":"TechCrunch","summary":"Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz - TechCrunch","headline":"Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOSWxxa2ZMUm01RFgwTkdxRVdsZWtEcW1xV0ZxT0x3UHUzY01QV19FcUc2d3NhWmV6alA0WGhlalkzZ252UVNoZ1BxcXJTVHdRYmRTQksyYXk2WWhIdDg3c3d1a3ppUThvOExxVDBzdENLXzh1M2UyQkRBMVFHMVllQ2o4YmtGNnNtNmpDM0RBbUdIMGlQcHlnNzY3YjlPMG1DUWs4cHVBbWhKMXB2cE9lcFlnRS11QWFrOXpkYWtyUEZSODJBTXNxcDZmZEFMcGJ4S24yOXVmNlpHR2k5WGRuQTg2YmNhTE0weEZaNFgyTW0?oc=5","date":"2025-09-08","type":"pipeline","source":"PR Newswire","summary":"Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPdzhXM3gtWExGZ2ZCdVhZWGpEMlZXSjdtcnlaMXV1UHo2M0IwemtlZkVUbVdqV2dzUF9ObUttWkxaNmI4cVhYbkYyUlkzbEVtM0hoZUp6WVhCaWRsUGM5RmwxT1B3QVpPclJrV19IZ21aLWt6bXFUTm15YWtVemU4cG9OUjVkZ09uUWlCdUY4akctVkhTVkJSeFlHV3RpZWRXOW9PbFFfalZkQQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Fierce Pharma","summary":"Connect Biopharma joins NFL star Ickey Woods for asthma education blitz - Fierce Pharma","headline":"Connect Biopharma joins NFL star Ickey Woods for asthma education blitz","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQTkxOdEpnVUozd19kX3hJRnZiUGhOX2N6ZkRibHNYdmF4ZElJU3lDdmtWLXJJTktLVlBWLWNpbF80bFduTVZuWktVb2MzNlhkYXJJZ2FKd1NTQjA5Sk85N3EtZjVURUc1V2hOTFo4TUNicTlTVWJWR2RkVVNLRU8zLXRKNS1VNGVXQXVES2h6cWpCQQ?oc=5","date":"2025-07-09","type":"deal","source":"Yahoo Finance","summary":"Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China - Yahoo Finan","headline":"Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Applicatio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOUHhjSDlhVWFsemJLejdkaHphZXFQcHJCa2hYV25hTUIxTUFhYTdHZ0JNNjVrSmpMTlktM09kUHBLLXFnSGV5TmYtZWExZ0VzNFVnclMxMTg4anNzVnVqVmczZHpCN1c5SFlEdDhnVWlFOGlrWVlNeURRMmk2bGZ1SjQzdDNTc1FoY1pYVEFYUWdDcjNBbGZPeEt4OU9icTF5VGRZ?oc=5","date":"2024-09-06","type":"pipeline","source":"Fierce Biotech","summary":"Connect reduces China workforce, mulls strategy for potential Dupixent rival - Fierce Biotech","headline":"Connect reduces China workforce, mulls strategy for potential Dupixent rival","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1wUHAxRnFoNzZWSHNESjhta1dNMC1QZjlvVHI4T1NKeEwtSUVONHh1Qy01RzdqXy1XQm10aVJKRDVNU3pZZ3ZfUWs1dndKRmlLS2NsWElqNnljWk1pZkVn?oc=5","date":"2023-07-31","type":"pipeline","source":"Nature","summary":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases - Nature","headline":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody target","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}